vs
AbCellera Biologics Inc.（ABCL）与Amarin Corp plc（AMRN）财务数据对比。点击上方公司名可切换其他公司
Amarin Corp plc的季度营收约是AbCellera Biologics Inc.的1.0倍（$45.1M vs $44.9M），AbCellera Biologics Inc.净利率更高（-19.9% vs -23.3%，领先3.3%），AbCellera Biologics Inc.同比增速更快（788.4% vs 7.0%），过去两年AbCellera Biologics Inc.的营收复合增速更高（112.3% vs -18.3%）
AbCellera Biologics是一家总部位于不列颠哥伦比亚省温哥华的生物科技企业，核心业务是探索与开发抗体治疗药物。该公司凭借 proprietary 技术平台可在60天内开发出医疗应对方案，其单细胞筛选技术平台最早诞生于不列颠哥伦比亚大学，还曾作为核心力量参与美国国防高级研究计划局的大流行预防平台项目。
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
ABCL vs AMRN — 直观对比
营收规模更大
AMRN
是对方的1.0倍
$44.9M
营收增速更快
ABCL
高出781.4%
7.0%
净利率更高
ABCL
高出3.3%
-23.3%
两年增速更快
ABCL
近两年复合增速
-18.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $44.9M | $45.1M |
| 净利润 | $-8.9M | $-10.5M |
| 毛利率 | — | — |
| 营业利润率 | -63.7% | 35.5% |
| 净利率 | -19.9% | -23.3% |
| 营收同比 | 788.4% | 7.0% |
| 净利润同比 | 73.9% | 33.0% |
| 每股收益（稀释后） | $-0.03 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABCLAMRN
| Q1 26 | — | $45.1M | ||
| Q4 25 | $44.9M | $49.2M | ||
| Q3 25 | $9.0M | $49.7M | ||
| Q2 25 | $17.1M | $72.7M | ||
| Q1 25 | $4.2M | $42.0M | ||
| Q4 24 | $5.0M | $62.3M | ||
| Q3 24 | $6.5M | $42.3M | ||
| Q2 24 | $7.3M | $67.5M |
净利润ABCLAMRN
| Q1 26 | — | $-10.5M | ||
| Q4 25 | $-8.9M | $-1.2M | ||
| Q3 25 | $-57.1M | $-7.7M | ||
| Q2 25 | $-34.7M | $-14.1M | ||
| Q1 25 | $-45.6M | $-15.7M | ||
| Q4 24 | — | $-48.6M | ||
| Q3 24 | $-51.1M | $-25.1M | ||
| Q2 24 | $-36.9M | $1.5M |
毛利率ABCLAMRN
| Q1 26 | — | — | ||
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 44.7% | ||
| Q2 25 | — | 69.2% | ||
| Q1 25 | — | 59.8% | ||
| Q4 24 | — | -15.4% | ||
| Q3 24 | — | 38.5% | ||
| Q2 24 | — | 63.4% |
营业利润率ABCLAMRN
| Q1 26 | — | 35.5% | ||
| Q4 25 | -63.7% | -12.9% | ||
| Q3 25 | -851.8% | -22.4% | ||
| Q2 25 | -290.2% | -22.0% | ||
| Q1 25 | -1479.6% | -39.9% | ||
| Q4 24 | — | -84.3% | ||
| Q3 24 | -1439.4% | -59.5% | ||
| Q2 24 | -1276.2% | -0.8% |
净利率ABCLAMRN
| Q1 26 | — | -23.3% | ||
| Q4 25 | -19.9% | -2.5% | ||
| Q3 25 | -637.8% | -15.6% | ||
| Q2 25 | -203.3% | -19.4% | ||
| Q1 25 | -1077.2% | -37.4% | ||
| Q4 24 | — | -78.0% | ||
| Q3 24 | -785.4% | -59.4% | ||
| Q2 24 | -504.3% | 2.3% |
每股收益（稀释后）ABCLAMRN
| Q1 26 | — | — | ||
| Q4 25 | $-0.03 | $0.00 | ||
| Q3 25 | $-0.19 | $-0.02 | ||
| Q2 25 | $-0.12 | $-0.03 | ||
| Q1 25 | $-0.15 | $-0.04 | ||
| Q4 24 | — | $-0.12 | ||
| Q3 24 | $-0.17 | $-0.06 | ||
| Q2 24 | $-0.13 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $128.5M | $307.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $966.9M | — |
| 总资产 | $1.4B | $645.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABCLAMRN
| Q1 26 | — | $307.8M | ||
| Q4 25 | $128.5M | $302.6M | ||
| Q3 25 | $83.2M | $286.6M | ||
| Q2 25 | $92.4M | $298.7M | ||
| Q1 25 | $159.3M | $281.8M | ||
| Q4 24 | $156.3M | $294.2M | ||
| Q3 24 | $126.6M | $305.7M | ||
| Q2 24 | $148.3M | $306.7M |
股东权益ABCLAMRN
| Q1 26 | — | — | ||
| Q4 25 | $966.9M | $459.3M | ||
| Q3 25 | $964.0M | $458.9M | ||
| Q2 25 | $1.0B | $464.9M | ||
| Q1 25 | $1.0B | $473.7M | ||
| Q4 24 | $1.1B | $486.2M | ||
| Q3 24 | $1.1B | $531.4M | ||
| Q2 24 | $1.1B | $551.9M |
总资产ABCLAMRN
| Q1 26 | — | $645.8M | ||
| Q4 25 | $1.4B | $670.8M | ||
| Q3 25 | $1.4B | $659.8M | ||
| Q2 25 | $1.4B | $670.1M | ||
| Q1 25 | $1.3B | $655.7M | ||
| Q4 24 | $1.4B | $685.3M | ||
| Q3 24 | $1.4B | $750.6M | ||
| Q2 24 | $1.4B | $799.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-34.7M | — |
| 自由现金流经营现金流 - 资本支出 | $-44.6M | — |
| 自由现金流率自由现金流/营收 | -99.4% | — |
| 资本支出强度资本支出/营收 | 21.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-174.1M | — |
8季度趋势，按日历期对齐
经营现金流ABCLAMRN
| Q1 26 | — | — | ||
| Q4 25 | $-34.7M | $15.3M | ||
| Q3 25 | $-52.6M | $-12.7M | ||
| Q2 25 | $-32.4M | $16.6M | ||
| Q1 25 | $-11.6M | $-12.5M | ||
| Q4 24 | $-108.6M | $-13.3M | ||
| Q3 24 | $-28.9M | $-2.4M | ||
| Q2 24 | $-30.0M | $-2.7M |
自由现金流ABCLAMRN
| Q1 26 | — | — | ||
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-187.0M | — | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | — |
自由现金流率ABCLAMRN
| Q1 26 | — | — | ||
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -3702.8% | — | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | — |
资本支出强度ABCLAMRN
| Q1 26 | — | — | ||
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 1552.7% | — | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | — |
现金转化率ABCLAMRN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.81× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABCL
暂无分部数据
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
